| |
| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
|
|
relating to the designation of centers of excellence for the |
|
|
management and treatment of placenta accreta spectrum disorder. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. Chapter 32, Health and Safety Code, is amended by |
|
|
adding Subchapter G to read as follows: |
|
|
SUBCHAPTER G. CENTERS OF EXCELLENCE FOR MANAGEMENT AND TREATMENT |
|
|
OF PLACENTA ACCRETA SPECTRUM DISORDER |
|
|
Sec. 32.201. DEFINITION. In this subchapter, "placenta |
|
|
accreta spectrum disorder" includes placenta accreta, placenta |
|
|
increta, and placenta percreta. |
|
|
Sec. 32.202. DESIGNATION OF CENTERS OF EXCELLENCE. (a) The |
|
|
department, in consultation with the Texas Maternal Mortality and |
|
|
Morbidity Review Committee established under Chapter 34, shall |
|
|
designate as centers of excellence for the management and treatment |
|
|
of placenta accreta spectrum disorder one or more health care |
|
|
entities or programs in this state, including any institution or |
|
|
community hospital with the appropriate resources and personnel, as |
|
|
determined by the department and the review committee. |
|
|
(b) The executive commissioner, in consultation with the |
|
|
department and the Texas Maternal Mortality and Morbidity Review |
|
|
Committee, shall adopt rules necessary for a health care entity or |
|
|
program in this state to be designated as a center of excellence for |
|
|
management and treatment of placenta accreta spectrum disorder. |
|
|
Sec. 32.203. SUBCOMMITTEE. (a) The department, in |
|
|
consultation with the Texas Maternal Mortality and Morbidity Review |
|
|
Committee, shall appoint a subcommittee of the review committee to |
|
|
advise the executive commissioner on the adoption of rules under |
|
|
Section 32.202. As part of the subcommittee's duties under this |
|
|
subsection, the subcommittee specifically shall advise the |
|
|
executive commissioner on the criteria necessary for a health care |
|
|
entity or program in this state to be awarded a designation under |
|
|
this subchapter. |
|
|
(b) The subcommittee must consist of individuals with |
|
|
expertise in the management and treatment of placenta accreta |
|
|
spectrum disorder. A majority of the members of the subcommittee |
|
|
must practice in those areas in a health profession in this state. |
|
|
The subcommittee may include national and international experts. |
|
|
Sec. 32.204. PRIORITY CONSIDERATIONS FOR CENTER |
|
|
DESIGNATIONS. The rules adopted under Section 32.202 must |
|
|
prioritize awarding a designation under this subchapter to a health |
|
|
care entity or program that: |
|
|
(1) offers specialized management services for |
|
|
placenta accreta spectrum disorder through a multi-specialty |
|
|
clinical program and an associated hospital that provides advanced |
|
|
neonatal and maternal care in accordance with the hospital's level |
|
|
of care designation assigned under Section 241.182; |
|
|
(2) demonstrates a significant commitment to research |
|
|
in and advancing the field of care for placenta accreta spectrum |
|
|
disorder; |
|
|
(3) fosters telemedicine, referral, and transport |
|
|
relationships with rural hospitals in this state; and |
|
|
(4) integrates an advanced placenta accreta spectrum |
|
|
disorder management program with a program that provides |
|
|
appropriate long-term monitoring and follow-up care for patients. |
|
|
Sec. 32.205. REQUIREMENTS FOR CENTER DESIGNATION. The |
|
|
rules adopted under Section 32.202 must ensure that a health care |
|
|
entity or program in this state that receives a center of excellence |
|
|
designation under this subchapter: |
|
|
(1) provides or is affiliated with a hospital that |
|
|
provides advanced neonatal and maternal care in accordance with the |
|
|
hospital's level of care designation assigned under Section |
|
|
241.182; |
|
|
(2) establishes minimum criteria for medical, |
|
|
nursing, ancillary, and support staff, in addition to any other |
|
|
criteria required under Section 32.202; |
|
|
(3) measures short-term and long-term patient |
|
|
diagnostic and therapeutic outcomes; and |
|
|
(4) submits to the department annual reports |
|
|
containing aggregate data on short-term and long-term diagnostic |
|
|
and therapeutic outcomes as requested or required by the department |
|
|
and makes those reports available to the public on the entity's or |
|
|
program's Internet website. |
|
|
SECTION 2. (a) Not later than December 1, 2021, the |
|
|
Department of State Health Services, in consultation with the Texas |
|
|
Maternal Mortality and Morbidity Review Committee established |
|
|
under Chapter 34, Health and Safety Code, shall appoint members to |
|
|
the subcommittee as required by Section 32.203, Health and Safety |
|
|
Code, as added by this Act. |
|
|
(b) Not later than September 1, 2022, the executive |
|
|
commissioner of the Health and Human Services Commission shall |
|
|
adopt rules as required by Section 32.202, Health and Safety Code, |
|
|
as added by this Act. |
|
|
(c) Not later than September 1, 2022, the Department of |
|
|
State Health Services shall begin awarding designations of centers |
|
|
of excellence as required by Subchapter G, Chapter 32, Health and |
|
|
Safety Code, as added by this Act. |
|
|
SECTION 3. This Act takes effect September 1, 2021. |